Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings tomorrow morning. Here’s what ...

According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual ...

Glenmark launches Latanoprost Ophthalmic Solution, targeting $113.5 million market, showcasing commitment to quality eye care ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin ...

Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services.

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.

Glenmark Pharma introduces generic Xalatan ophthalmic solution, 0.005% in US: Our Bureau, Mumbai Friday, February 14, 2025, 12:15 Hrs [IST] Glenmark Pharmaceuticals Inc., USA (Gle ...

Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

These issues were primarily attributed to reorganizations within large pharmaceutical companies and reduced spending in the biopharma sector. Analysts have noted that while IQVIA is less dependent on ...

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of clindamycin phosphate foam, 1%. Glenmark’s clindamycin phosphate foam, 1% is bioequivalent and therapeutically equivalent to the ...